These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 11067902)

  • 1. Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo.
    Fallarino F; Grohmann U; Bianchi R; Vacca C; Fioretti MC; Puccetti P
    J Immunol; 2000 Nov; 165(10):5495-501. PubMed ID: 11067902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.
    Surman DR; Dudley ME; Overwijk WW; Restifo NP
    J Immunol; 2000 Jan; 164(2):562-5. PubMed ID: 10623795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfer of IFNgamma-depleted CD4(+) T cells together with CD8(+) T cells leads to rejection of murine kidney sarcoma in mice.
    Klugewitz K; Scheffold A; Radbruch A; Hamann A
    Int J Cancer; 2000 Sep; 87(5):673-9. PubMed ID: 10925361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells.
    Bianchi R; Grohmann U; Belladonna ML; Silla S; Fallarino F; Ayroldi E; Fioretti MC; Puccetti P
    J Immunol; 1996 Aug; 157(4):1589-97. PubMed ID: 8759743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide.
    Grohmann U; Fioretti MC; Bianchi R; Belladonna ML; Ayroldi E; Surace D; Silla S; Puccetti P
    Crit Rev Immunol; 1998; 18(1-2):87-98. PubMed ID: 9419451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD8+ cell activation to a major mastocytoma rejection antigen, P815AB: requirement for tum- or helper peptides in priming for skin test reactivity to a P815AB-related peptide.
    Grohmann U; Bianchi R; Fioretti MC; Fallarino F; Binaglia L; Uyttenhove C; Van Pel A; Boon T; Puccetti P
    Eur J Immunol; 1995 Oct; 25(10):2797-802. PubMed ID: 7589074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy.
    Chamoto K; Kosaka A; Tsuji T; Matsuzaki J; Sato T; Takeshima T; Iwakabe K; Togashi Y; Koda T; Nishimura T
    Cancer Sci; 2003 Oct; 94(10):924-8. PubMed ID: 14556668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
    Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
    Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-specific CD4+ T cells have a major "post-licensing" role in CTL mediated anti-tumor immunity.
    Marzo AL; Kinnear BF; Lake RA; Frelinger JJ; Collins EJ; Robinson BW; Scott B
    J Immunol; 2000 Dec; 165(11):6047-55. PubMed ID: 11086036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen.
    Kennedy RC; Shearer MH; Watts AM; Bright RK
    Cancer Res; 2003 Mar; 63(5):1040-5. PubMed ID: 12615720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas.
    Schepers K; Toebes M; Sotthewes G; Vyth-Dreese FA; Dellemijn TA; Melief CJ; Ossendorp F; Schumacher TN
    J Immunol; 2002 Sep; 169(6):3191-9. PubMed ID: 12218137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-thyroid epithelial cell (TEC)-reactive CD8+ T cell lines/clones derived from autoimmune thyroiditis lesions. They recognize self-thyroid antigens directly on TEC to exhibit T helper cell 1-type lymphokine production and cytotoxicity against TEC.
    Sugihara S; Fujiwara H; Niimi H; Shearer GM
    J Immunol; 1995 Aug; 155(3):1619-28. PubMed ID: 7543527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of Th1 and Th2 L-selectin--CD4+ tumor-reactive T cells.
    To WC; Seeley BM; Barthel SW; Shu S
    Laryngoscope; 2000 Oct; 110(10 Pt 1):1648-54. PubMed ID: 11037819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
    Huang H; Li F; Gordon JR; Xiang J
    Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion.
    Wang LX; Chen BG; Plautz GE
    J Immunol; 2002 Sep; 169(6):3314-20. PubMed ID: 12218152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulatory T cells overexpress a subset of Th2 gene transcripts.
    Zelenika D; Adams E; Humm S; Graca L; Thompson S; Cobbold SP; Waldmann H
    J Immunol; 2002 Feb; 168(3):1069-79. PubMed ID: 11801640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells.
    Walker PR; Calzascia T; Schnuriger V; Scamuffa N; Saas P; de Tribolet N; Dietrich PY
    J Immunol; 2000 Sep; 165(6):3128-35. PubMed ID: 10975826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state.
    Grohmann U; Bianchi R; Ayroldi E; Belladonna ML; Surace D; Fioretti MC; Puccetti P
    J Immunol; 1997 Apr; 158(8):3593-602. PubMed ID: 9103420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T regulatory cells 1 inhibit a Th2-specific response in vivo.
    Cottrez F; Hurst SD; Coffman RL; Groux H
    J Immunol; 2000 Nov; 165(9):4848-53. PubMed ID: 11046008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.